MedTrace Logo

Safety of Bosentan in Type II Diabetic Patients

NCT04068272 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-02-16

No results posted yet for this study

Summary

This study evaluates the safety of topical Bosentan in Type II Diabetes patients

Conditions

Interventions

DRUG

Bosentan

Eyedrop

DRUG

Placebo

Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound

Sponsors & Collaborators

  • Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

    collaborator OTHER

  • Retinset SL

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-07
Primary Completion
2022-05-20
Completion
2022-05-20

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04068272 on ClinicalTrials.gov